{"url_path":"/sec/gwll/10-k/2026/item-1","section_key":"item-1","section_title":"Item 1 BUSINESS**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1800373/0001477932-26-004130-index.html","accession_number":"0001477932-26-004130","cik":"0001800373","ticker":"GWLL","issuer_name":"GOLDENWELL BIOTECH, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1800373/0001477932-26-004130-index.html","primary_entity_key":"0001800373","primary_entity_name":"GOLDENWELL BIOTECH, INC."},"word_count":1875,"has_tables":true,"body_markdown":"**ITEM 1. BUSINESS**\n\n \n\n**DESCRIPTION OF BUSINESS**\n\n \n\n**DESCRIPTION OF BUSINESS**\n\n \n\n**Our Corporate History and Background**\n\n \n\nGoldenwell Biotech, Inc. was incorporated on August 20, 2019. Our fiscal year end is December 31, and we have no subsidiaries. Our business offices are currently located at 7316 Capilano Dr., Solon, Ohio 44139. We do not conduction operations and only receive mail at such location.\n\n \n\n**Summary Financial Information**\n\n \n\nThe tables and information below are derived from our audited financial statements as of December 31, 2025.\n\n \n\n \n\n \n\n**December 31,**\n\n**2025**\n\n \n\n**Financial Summary**\n\n \n\n \n\n \n\nCash and Cash Equivalents\n\n \n$26,775\n \n\nTotal Assets\n\n \n\n \n26,775\n \n\nTotal Liabilities\n\n \n\n \n\n379,833\n\n \n\nTotal Stockholders’ Equity\n\n \n$\n(343,713\n)\n\n \n\n \n\n3\n\n*Table of Contents*\n\n \n\n**Exclusive Patent License Agreements**\n\n \n\nEffective July 20, 2020, the Company entered into an Exclusive License Agreement with Australian Trefoil Health Technologies Pty Ltd (the “Australian Trefoil License Agreement”), pursuant to which the Company has licensed from Australian Trefoil the technology and packaging designs underlying the Sugar Master and DNA Repair products, and other products of the Company. The term of the Australian Trefoil License Agreement is for the term of the underlying patent and covers all territories in the world, except China, and the term expires on November 15, 2025. The Company paid consideration of $10.00 for entering into the Australian Trefoil License Agreement. Australian Trefoil Health Technologies Pty Ltd is controlled by Li Yang, a director of the Company.\n\n \n\nAdditionally, effective July 20, 2020 the Company has entered into an Exclusive License Agreement, dated July 20, 2020, with Ji Lin JZY Biotech Inc. (the “JZY Biotech License Agreement”), pursuant to which the Company has licensed from JZY BioTech the technology the Company uses in its products. The term of the JZY BioTech License Agreement is for the term of the underlying patent and covers all territories in the world, except China, and the term expires on January 11, 2035. The Company paid consideration of $10.00 for entering into the JZY Biotech License Agreement. Ji Lin JZY Biotech Inc. is controlled by Shang Liu, our President and Chief Executive Officer and a director of the Company.\n\n \n\n**Status of Production**\n\n \n\nEach of our 5 products discussed below have been completed the following stages:\n\n \n\n \n\n·\n\nWe have concluded our initial marketing analysis, including an analysis of our competition and development of marketing strategies.\n\n \n\n·\n\nWe have concluded our research and development, including making a raw materials selection, making products formulations, concluding lab testing, and concluding quality assurance and quality control studies.\n\n \n\n·\n\nWe have concluded the parts of production, including the production process, producing technology optimization, selection equipment for production; selecting sources of raw materials supplies.\n\n \n\nwhich includes locating a site, installing a workshop and setting up equipment. No special equipment needs to be engineered or produced. All needed equipment is presently available from existing manufacturers. Second, our workforce will need to be trained, however, no specialized education or experience is needed by labor we intend to hire.\n\n \n\n**Goldenwell Products**\n\n \n\nCategory I Polypeptide Freeze-dried Powder\n\n \n\n**1. JI MAI—Bovine Cardiac Vascular Active Peptide**\n\n \n\nFigure 1 – packaging design for Ji Mai Cardiac Vascular Active Peptide\n\n \n\n \n\n4\n\n*Table of Contents*\n\n \n\nThe vascular endothelial cells exist vascular wall of bovine have a complex enzyme system, which can synthesize and secrete a variety of bioactive substances, as well as tissue fibrinogen and prostacyclin, endothelin (which has a strong vasoconstrictive effect, also known as endothelium contraction factor), and vascular skin cell relaxation factor which has vasodilated effect.\n\n \n\nBovine cardiac vascular active peptide is a protein peptide of vascular homology (amino acid type and its sequence) which made from healthy and fresh bovine cardiac vascular tissues as raw materials. It is made in a closed environment at low temperature using medical freeze-dried equipment and is processed through biological enzymolysis, enzyme digestion, separation, purification, ultrafiltration and other extraction process to structural polypeptide in a freeze-dried powder form. The molecular weight of the product is optimized via bioengineering for easy absorption by humans. There is no pigment, preservatives and other artificial additives in the product, and is suitable for all kinds of physical conditions of people to use.\n\n \n\nBiocompatibility (amino acid sequence and structure convergence of peptides) refers to the good matching degree between basic protein peptides and host cells and tissues. Whether it is the skeleton of new tissue before being absorbed, or it is absorbed and assimilated into the host to become a part of the host, it has good compatibility with the matrix of similar tissue, and becomes a part of the normal physiological function of cells and tissues.\n\n \n\n**2. Double Proline AG – 3D Active Collagen Peptide**\n\n \n\nDPAG - Drinkable Cosmetics\n\n \n\n \n\nFigure 2 - packaging design for 3D Active Collagen Peptide\n\n \n\nThere is a substance in human body called cathepsin K, which is slowly degrading collagen content of tissue while ageing. It will result that active collagen is gradually reduced and lost. The appearance of the body is the loss of elasticity, relaxation and relaxation of the body. The interior of the body is the decrease of the cell quantity and the collapse of the tissue.\n\n \n\nSea cucumber, deer tendon, eel, fish maw, donkey skin all have significant common characteristics – gelatinous consistencies, which contains higher proline, hydroxyproline, arginine and glycine. In mammals, ox tendon has the highest content of collagen.\n\n \n\n80% of the human skin made by collagen; the molecular weight of collagen in glial food is 300000 daltons. The molecular size of the gliadin food is too large, it is very difficult for human digestive enzymes to decompose it, and its digestion and absorption rate is very limited.\n\n \n\n \n\n5\n\n*Table of Contents*\n\n \n\nBy using healthy and fresh bovine or ox tendon as raw materials, our DPAG product is made in a closed environment at low temperature using medical freeze-dried equipment and was processed through biological enzymolysis, enzyme digestion, separation, purification, ultrafiltration and other extraction process to structural polypeptide in a freeze-dried powder form. The molecular weight of the product is 1920da and is optimized via the bioengineering technical for easy absorption by humans. There is no pigment, preservatives and other artificial additives in the product.\n\n \n\nOur DPAG product is designed to be an easily absorbed bioactive collagen.\n\n \n\n**3. Cartilage Peptide -- Type II collagen peptide**\n\n \n\n \n\nFigure 3 - packaging design for Cartilage Peptide -- Type II collagen peptide\n\n \n\nIn recent years, there are many collagen (peptide) products on the market, but they are basically raw materials for collagen production. Most of them come from fish skin and other raw materials.\n\n \n\nType II collagen peptide is prepared from Bovine or Pig Cartilage bones by hot water extraction, and then it is enzymolyzed by neutral protease, protamex, acidic protease and pepsin, through purification, ultrafiltration and other extraction process to structural polypeptide in a freeze-dried powder form peptide with molecular weight of 8000 daltons.\n\n \n\nIt mainly composed of type II collagen peptide from cartilage and bone; it has a higher content of bio calcium with collagen peptides acting as a dietary supplement.\n\n \n\n \n\n6\n\n*Table of Contents*\n\n \n\nCategory II Solid Tablets Products\n\n \n\nFigure 4 - packaging design for Se Plus\n\n \n\nSe Plus utilizes the stabilizing properties of the 21st amino acids and strong antioxidants as its primary makeup.\n\n \n\nIngredients:\n\n \n\n \n\n·\n\nL-Se-Methylselenocysteine (MSC)\n\n \n\n·\n\nHigh Selenium Yeast\n\n \n\nL-Se-Methylselenocysteine (MSC) is a naturally occurring organoselenium compound found in many plants, including garlic, onions, and broccoli, with potential antioxidant and chemopreventive activities. Se-Methyl-seleno-L-cysteine (MSC) is an amino acid analogue of cysteine in which a methylselenium moiety replaces the sulphur atom of cysteine. This agent acts as an antioxidant when incorporated into glutathione peroxidase and has been shown to exhibit potent chemopreventive activity in animal models.\n\n \n\nSe Plus Target Audience:\n\n \n\n \n\n·\n\nMiddle-aged and elderly individuals.\n\n \n\n·\n\nIndividuals exposed to excessive pollution, such as atmospheric, food, or water pollution.\n\n \n\n·\n\nIndividuals who are selenium deficient due to various reasons.\n\n \n\n \n\n7\n\n*Table of Contents*\n\n \n\n**2. Sugar Master**\n\n \n\n \n\nFigure 5 - packaging design for Sugar Master\n\n \n\nOur Sugar Master product is made utilizing low temperature extraction techniques to maximize the harvest of bio-actives of plant matter, which is optimized by our processing formula to ensure the best absorption as a dietary supplement.\n\n \n\nMain Active Ingredients Include:\n\n \n\n \n\n·\n\nNatural herbal polypeptides, extracted using cryogenic techniques to ensure molecular activity;\n\n \n\n·\n\nConcentrated and purified natural plant extracts; and\n\n \n\n·\n\nHigh efficiency organic selenium complex.\n\n \n\nTwo major components of bitter melon, namely charantin and momordicoside, may be destroyed during the process of extraction if high temperatures are used (60 C for 24 hours by heat drying). These components should therefore be extracted safely at low temperatures (5 C for 24 hours by freeze-drying or lyophilization).\n\n \n\n**COMPETITION AND COMPETITIVE STRATEGY**\n\n \n\nWe expect that we will compete for members with traditional, offline consumer resources, and with online providers of consumer ratings, reviews and referrals on the basis of a number of factors, including breadth of our service provider listings, reliability of our content, breadth, depth and timeliness of information and strength and recognition of our brand.\n\n \n\n**Intellectual Property**\n\n \n\nWe rely on a combination of trademark laws, trade secrets, confidentiality provisions and other contractual provisions to protect our proprietary rights, which are primarily our brand names, product designs and marks. We do not own any patents.\n\n \n\nEffective July 20, 2020, the Company entered into an Exclusive License Agreement with Australian Trefoil Health Technologies Pty Ltd (the “Australian Trefoil License Agreement”), pursuant to which the Company has licensed from Australian Trefoil the technology and packaging designs underlying the Sugar Master and DNA Repair products, and other products of the Company. The term of the Australian Trefoil License Agreement is for the term of the underlying patent and covers all territories in the world, except China, and the term expires on November 15, 2025. The Company paid consideration of $10.00 for entering into the Australian Trefoil License Agreement. Australian Trefoil Health Technologies Pty Ltd is controlled by Li Yang, a director of the Company.\n\n \n\n \n\n8\n\n*Table of Contents*\n\n \n\nAdditionally, effective July 20, 2020 the Company has entered into an Exclusive License Agreement, dated July 20, 2020, with Ji Lin JZY Biotech Inc. (the “JZY Biotech License Agreement”), pursuant to which the Company has licensed from JZY BioTech the technology the Company uses in its products. The term of the JZY BioTech License Agreement is for the term of the underlying patent and covers all territories in the world, except China, and the term expires on January 11, 2025. The Company paid consideration of $10.00 for entering into the JZY Biotech License Agreement. Ji Lin JZY Biotech Inc. is controlled by Shang Liu, our President and Chief Executive Officer and a director of the Company.\n\n \n\n**Government Regulation and Approvals**\n\n \n\nWe are not aware of any governmental regulations or approvals required for any of our services or products. We do not believe that we are subject to any government regulations relating to the ownership and licensing of our intellectual property.\n\n \n\n**Employees**\n\n \n\nAs of the date hereof, we have 3 non-employee officers, who operate our company. \n\n \n\n**Description of Properties**\n\n \n\nWe have an address at 7316 Capilano Dr., Solon, Ohio 44139. We do not conduction operations and only receive mail at such location. Our telephone number is (440) 666-7999. We do not own any real estate or other physical properties.\n\n \n\n \n\n**Bankruptcy or Similar Proceedings**\n\n \n\nWe have never been subject to bankruptcy, receivership or any similar proceeding."}